M Ventures — 2020 Investments
3 investments dated 2020 · listed companies and verified rows first · show all
Xilio Therapeutics is a clinical-stage biotechnology company developing masked immuno-oncology therapies that use protein engineering to remain inactive until activated by tumor-specific proteases within the tumor microenvironment.
BiotechHealthtechWaltham, US
René Russo(Executive Officer, Director)inJoseph Farmer(Executive Officer)Timothy Clackson(Executive Officer)Christopher Frankenfield(Chief Financial and Operating Officer)inKatarina Luptakova(Chief Medical Officer)inPaul Clancy(Director)
Co-investorsBain Capital Life SciencesBay City CapitalF-Prime CapitalMRL Ventures FundRA CapitalRiverVest Venture Partners+9 more
Co-investorsAndera PartnersFountain Healthcare PartnersPMV
FoRx Therapeutics is a biotechnology company focused on oncology drug discovery and clinical development, targeting the DNA Damage Response (DDR) network with small molecule inhibitors.
BiotechDeep TechHealthtechBasel, CH
Tarig Bashir(Chief Executive Officer (CEO))inJens Würthner(Chief Medical Officer (CMO))Frank Zenke(Chief Scientific Officer (CSO))in
Co-investorsNovartis Venture FundPfizer Venture InvestmentsOmega Funds
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.